$AGIO news
The latest AGIO stock news: headlines, filings, AI summaries and sentiment for $AGIO, updated around the clock.
- Agios Reports Q3 2026 Revenue Surge Driven by Thalassemia Product Launch
- AGIOS PHARMACEUTICALS, INC. - 10-Q Filing
- Agios Pharmaceuticals Reports Third Quarter Revenue Growth and EPS Beat
- AGIOS PHARMACEUTICALS, INC. - 8-K Filing
- Agios Pharmaceuticals Scheduled to Report Q3 2026 Earnings on November 5
- Agios Pharmaceuticals Shares Drop Following FDA Review Extension for Pyrukynd
- Four High-Risk Stocks With Potential for Significant Returns
- AGIOS PHARMACEUTICALS, INC. - 10-Q Filing
- AGIOS PHARMACEUTICALS, INC. - 8-K Filing
- Agios Pharmaceuticals Shares Rise on FDA Priority Review for Mitapivat in Sickle Cell Disease
- Agios Pharmaceuticals Stock Rises on FDA Priority Review for Mitapivat in Sickle Cell Disease
- Agios Pharmaceuticals Stock Rises on FDA Acceptance of Mitapivat Supplemental NDA
- Agios Pharmaceuticals Shares Rise on Strong Q1 Earnings and Aqvesme Launch Progress
- Agios Pharmaceuticals Shares Rise on Strong Earnings and Aqvesme Launch
- Agios Pharmaceuticals Stock Rises 13% After Strong Q1 Earnings Report
- Agios Pharmaceuticals Q1 Earnings Report and Pipeline Updates
- Agios Reports Q1 2026 Earnings Results with Strong Revenue Growth
- Agios Pharmaceuticals Reports Strong Q1 Revenue Growth and Shares Rise 13%
- Agios Pharmaceuticals Reports Q1 GAAP EPS of -$1.69 and Revenue of $20.75M
- Agios Pharmaceuticals Stock Slumps After Novo Nordisk's Superior SCD Drug Results
- Agios Pharmaceuticals Stock Slumps After Novo Nordisk Announces Superior Sickle Cell Drug
- Agios Pharmaceuticals (AGIO) Reports Q3 2024 Earnings Call Details
- Agios (AGIO) Reports Q2 2025 Earnings with Revenue Growth and Pipeline Advancement
- Agios Reports Q3 2025 Earnings with Revenue Growth and Regulatory Updates
- Wingstop (WING) Q2 2025 Earnings Report Highlights Revenue Growth and Strategic Partnerships
- Agios Pharmaceuticals Shares Drop 23% Following Novo Nordisk's Positive Trial Results
- Agios Pharmaceuticals Shares Drop 23% After Novo Nordisk's Sickle Cell Trial Results